Omeros Corporation

XNASHealth care

Last traded price · USD

$17.11

−5.87%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 22:51 IST · A quote does not mean the product is available to trade on your account.

Day's open: $18.05
Previous close: $18.18
Volume: 442,793
Day's high: $18.05
Day's low: $16.97

In brief

Omeros Corporation is a health care company listed on Nasdaq, valued at about $1.24B.
Its shares closed at $18.18 on 4 Nov 2026, up 170.1% over the past year.
From India you can buy OMER in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Omeros Corporation (OMER) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole OMER share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade OMER options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −1.8% (SPY −1.6%, XLV +13.5%). 3 months: +43.7% (SPY −0.4%, XLV +15.5%). 1 year: +170.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: OMER, SPY and XLV · as of 4 Nov 2026
12.2 days to cover short interest
11.4M shares were sold short at the 15 Oct 2026 settlement, 15.8% of the 72.4M shares outstanding; covering them would take 12.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.9× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 3.6M shares was 2.9× the average of the 30 sessions before it (1.2M), as the price rose 6.0%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $18.18 was 1.5% below its 50-day average ($18.45) and 33.9% above its 200-day average ($13.58). It has closed above the 200-day for 72 sessions, since 27 Jul 2026. The 50-day average crossed above the 200-day on 20 Aug 2026, 53 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
80% of the way up its 52-week range
Closed at $18.18 on 4 Nov 2026: 14.4% below the 52-week high of $21.24 (22 Sep 2026) and 191.3% above the low of $6.24 (13 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−1.8%

6 months+22.6%

1 year+170.1%

5 years+142.1%

Newswire

About

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Website

Notable moves

December 24, 2025
+75.54%
October 15, 2025
+154.15%
July 1, 2022
+68.73%

Newswire

About

Website

Notable moves

December 24, 2025
+75.54%
October 15, 2025
+154.15%
July 1, 2022
+68.73%

Omeros Corporation

XNASHealth care

Last traded price · USD

$17.11

−5.87%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 22:51 IST · A quote does not mean the product is available to trade on your account.

Day's open: $18.05
Previous close: $18.18
Volume: 442,793
Day's high: $18.05
Day's low: $16.97

In brief

Omeros Corporation is a health care company listed on Nasdaq, valued at about $1.24B.
Its shares closed at $18.18 on 4 Nov 2026, up 170.1% over the past year.
From India you can buy OMER in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Omeros Corporation (OMER) shares from India?

Do I need the price of a whole OMER share to invest?

How much can I invest in US stocks in a year?

Can I trade OMER options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −1.8% (SPY −1.6%, XLV +13.5%). 3 months: +43.7% (SPY −0.4%, XLV +15.5%). 1 year: +170.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: OMER, SPY and XLV · as of 4 Nov 2026
12.2 days to cover short interest
11.4M shares were sold short at the 15 Oct 2026 settlement, 15.8% of the 72.4M shares outstanding; covering them would take 12.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.9× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 3.6M shares was 2.9× the average of the 30 sessions before it (1.2M), as the price rose 6.0%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $18.18 was 1.5% below its 50-day average ($18.45) and 33.9% above its 200-day average ($13.58). It has closed above the 200-day for 72 sessions, since 27 Jul 2026. The 50-day average crossed above the 200-day on 20 Aug 2026, 53 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
80% of the way up its 52-week range
Closed at $18.18 on 4 Nov 2026: 14.4% below the 52-week high of $21.24 (22 Sep 2026) and 191.3% above the low of $6.24 (13 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−1.8%

6 months+22.6%

1 year+170.1%

5 years+142.1%

Newswire

About

Website

Notable moves

December 24, 2025
+75.54%
October 15, 2025
+154.15%
July 1, 2022
+68.73%

Newswire

About

Website

Notable moves

December 24, 2025
+75.54%
October 15, 2025
+154.15%
July 1, 2022
+68.73%

Omeros Corporation

Omeros Corporation in brief

Ahead of SPY and its sector fund XLV over 1 year

12.2 days to cover short interest

Volume 2.9× its 30-session average on 29 Oct 2026

Below its 50-day average, above its 200-day

80% of the way up its 52-week range

Omeros Corporation

Omeros Corporation in brief

Ahead of SPY and its sector fund XLV over 1 year

12.2 days to cover short interest

Volume 2.9× its 30-session average on 29 Oct 2026

Below its 50-day average, above its 200-day

80% of the way up its 52-week range